Quince Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Quince Therapeutics announced the discontinuation of its eDSP program for A-T due to unsuccessful Phase 3 trial results and is now exploring strategic alternatives, including a reverse merger.
NASDAQ
10-K: Quince Therapeutics Reports Fiscal Year 2024 Results, Focuses on eDSP Development for Rare Diseases
Quince Therapeutics details its 2024 activities, highlighting the Phase 3 NEAT trial for eDSP in A-T and strategic focus on rare disease treatments.
NASDAQ
Quince Therapeutics, Inc. released its 10-K filing for fiscal year 2023, highlighting its strategic shift towards rare disease therapeutics and the advancement of its lead asset, EryDex.